INTRODUCTION
Invasive fungal infection remains a serious concern in the neonatal intensive care unit (NICU) with an incidence among very low-birth-weight (<1500 g) infants estimated to be 2 to 9%. 1, 2 Previous studies have demonstrated that premature infants are at significant risk for the development of fungal infection. [1] [2] [3] [4] [5] However, systemic candidiasis may be under-reported, as previous studies have indicated that only 50 to 80% of infected patients have positive blood cultures, and only 70% of those with meningeal involvement have positive cerebrospinal fluid (CSF) cultures. 6 Furthermore, many medical therapies that are often considered essential in the care of the premature neonate, including use of broad-spectrum antibiotics and placement of central vascular catheters, are also considered risk factors for the development of fungal infection. [1] [2] [3] [4] 7, 8 But, the serious consequences of fungal infection cannot be disputed, with mortality rates for very lowbirth-weight neonates with candidemia ranging from 25% to 75%. [3] [4] [5] 9 The occurrence of end-organ involvement and morbidities associated with candidal infection is less well defined, documented most often in case reports and small clinical series. There have been reports of neonates with candidal lens and retinal involvement, [10] [11] [12] [13] [14] but information regarding the incidences and natural history of candidal renal mycetoma, fungal endocarditis, and fungal brain abscesses among neonates is limited. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Ancillary testing including retinal examination, abdominal ultrasound and echocardiogram for all infants with candidemia has been suggested. 23 However, due to the uncertainty regarding the occurrence and severity of morbidities associated with invasive candidiasis, there is no consensus regarding the approach to ancillary diagnostic testing for infants with a positive blood, urine or CSF culture for a Candida species. 25 In this single-center, retrospective analysis, we report the incidence and yield of ancillary testing and examinations for fungal organ involvement among NICU patients with a positive body fluid culture for Candida. We also describe the study group with respect to sources and number of positive cultures, and Candida species isolated.
METHODS
This was a retrospective review of the NICU infectious disease database at Lucile Salter Packard Children's Hospital at Stanford to identify all patients with cultures of blood, urine, CSF, peritoneal fluid, or endotracheal tube (ETT) aspirate positive for a Candida species from January 1, 1997 to January 6, 2002. Data regarding the source and number of positive cultures, and the type of fungal species isolated were also noted. Initial blood cultures may have been obtained either peripherally or by indwelling arterial or central venous catheters, but follow-up cultures were obtained by peripheral sampling. Urine cultures were obtained only by suprapubic aspiration or sterile bladder catheterization. ''Clean catch'' or ''bag'' urine specimens were not obtained for the purposes of culture. Although not commonly reported, ETT aspirate results were also included. Growth of Candida from an ETT aspirate has been shown to be associated with increased risk for development of systemic candidiasis in very low-birth-weight infants. 26 ETT aspirates in this analysis were obtained only if the patient exhibited respiratory decompensation and chest radiograph abnormalities, and if the ETT had been placed within 24 hours. One culture in this series was obtained by bronchoscopy.
The extent and results of ancillary testing for organ fungal dissemination were also investigated. For each positive Candida culture case identified, the radiology records were reviewed to determine if echocardiogram, head ultrasound (HUS) or other brain imaging, and renal ultrasound (RUS) had been performed, and the findings were documented. The timing of these studies with respect to the positive fungal cultures was noted. The medical records were also reviewed to ascertain occurrence, timing and results of ophthalmologic examination. Descriptive statistics were performed using StatView Version 5.0.1 (SAS, Cary NC).
RESULTS

Culture Results
During the study period, approximately 8120 patients were admitted to the NICU. The overall incidence of a positive culture for Candida in our intensive care nursery during the study period was 8.6/1000 admissions (0.86%), comparable to the 1.1% of all NICU admissions reported by others. 7 There were a total of 66 patients identified with at least one positive culture for a species of Candida, with 207 cultures positive among the patients identified. Five species of Candida were identified: C. albicans (47 patients), C. parapsilosis (14 patients), C. glabrata (three patients), C. lusitaniae (two patients) and C. tropicalis (one patient). One patient had cultures positive for both C. lusitaniae and C. albicans. The most frequent source was blood (138 cultures in 38 patients), followed by urine (46 cultures in 33 patients), peritoneal fluid (13 cultures in one patient), ETT (six cultures in five patients), and CSF (four cultures in four patients).
Of the 66 patients identified, 51 (77.3%) had a positive culture from one site only, 14 (21.2%) had positive cultures from two sites, and one (1.5%) had positive cultures from three sites ( Table 1) . Considering positive Candida species cultures from any site, 39.4% (26/66) of patients had a total of one positive culture, 22.7% (15/66) had two positive cultures, 10.6% (7/66) had three positive cultures, 9.1% (6/66) had four positive cultures, 7.6% (5/66) had five positive cultures, 1.5% (1/66) of patients had six positive cultures. Six patients (9.1%) had more than six positive cultures. The number of positive cultures per patient from a single source ranged from one to 16. Of the 12 patients with only one blood culture positive for Candida, six of the cultures were obtained by peripheral sampling. In three patients, blood was obtained by peripheral arterial line (in one), or central venous line (in two); however, in those patients urine fungal cultures were also positive. In two patients, blood was obtained by peripheral arterial line, and no other cultures were positive. The last patient was heparinized on extracorporeal membrane oxygenation, therefore peripheral blood sampling was not possible; in this case, a bronchoscopy specimen was also positive.
Patients
Birth weights of the study population ranged from 337 to 4025 g (mean±standard deviation (SD), 1327±987 g). Very low-birthweight infants accounted for 71.2% (47/66) of the patients identified. The gestational age of the patients ranged from 23 to 40 weeks (29.5±5.6 weeks). Among this high-risk population, 16 of the 66 patients (24.2%) died before hospital discharge. In four of these patients (6.1%), fungal infection was considered to have been a contributor to death; this was reflected in the medical record as a 
Ancillary Tests
Echocardiograms were obtained in 54 of 66 (82%) patients ( Table 2 ). The number of days from first positive fungal culture to echocardiogram ranged from 1 to 34 days (4.6±6.5 days), with examinations in 46 of the 54 patients obtained within 7 days. No study was positive for intracardiac thrombi, vegetations, or endocarditis. Of the 12 patients who did not undergo echocardiograms, only three had a positive fungal blood culture. Two of these infants died very soon after fungal infection was diagnosed; one, an extremely preterm infant with severe intraventricular hemorrhages and lung disease, and the other, an infant with complex congenital heart disease, DiGeorge's syndrome, encephalopathy, seizures, and renal failure. The remaining patient had undergone bowel resection for Hirschsprung's disease, and had negative repeat blood cultures after initiation of amphotericin B and the removal of a central venous catheter. Ophthalmology examinations were obtained in 36 of 66 (55%) patients to investigate for fungal involvement. None of these examinations was consistent with fungal involvement.
HUS were performed in 46/66 (70%) of the patients. The examinations were obtained from 1 to 31 days (mean±SD ¼ 5.1±5.3 days) after the first positive fungal culture, with the examinations of 38 of the 46 obtained within 7 days. There was only one HUS consistent with intracranial fungal involvement, in a patient who had had a total of 16 positive blood cultures for C. albicans. The first ultrasound performed 2 days after the first positive blood culture was negative; however, another HUS performed on day 17 after persistently positive blood cultures demonstrated a hemorrhagic, necrotic area within the cerebral cortex. Brain magnetic resonance imaging (MRI) results were consistent with a mycotic aneurysm. This patient also had an echocardiogram, RUS and an ophthalmologic examination, all of which were negative for fungal involvement. The infant, who had complex congenital heart disease, a chromosomal anomaly, and had undergone duodenoduodenostomy for duodenal atresia, expired in the NICU 61 days after the first positive fungal blood culture. Of note, this patient did not have a positive CSF culture for Candida although seven CSF cultures were obtained from the time of the first positive fungal blood culture until death. Brain MRI's, but not HUS, were performed in an additional four patients 4 to 15 days after the first positive fungal culture. None of these studies was positive for fungal involvement. Thus, brain imaging of some type was performed in 50/66 patients (76%). Only five of the 16 patients who did not undergo any brain imaging subsequent to fungal infection had had positive blood cultures; two died very soon after diagnosis of fungal infection, and the remaining three had documented negative blood cultures on antifungal therapy and after central venous catheters were removed. Brain imaging was performed in all four of the patients with a history of a positive fungal CSF culture.
RUS were performed in 58/66 (88%) of patients. The studies were performed from 1 to 34 days (mean±SD ¼ 4.5±6.1 days) after the first positive fungal culture, with the examinations of 51 of the 58 patients obtained within 7 days. There were concerning findings for fungal renal involvement in nine of the patients. However, in two of these, the ultrasound findings were subsequently reinterpreted not to be consistent with fungal organ involvement. Of the remaining seven patients who had positive studies (Table 3) , the source of the positive fungal culture that led to ancillary testing was urine in five patients, and CSF and urine in one. In one patient the source was blood, but neither CSF nor suprapubic bladder aspiration could be safely obtained prior to initiation of antifungal therapy and ancillary testing due to the extremely critical condition of the patient at the time of the positive culture. For the seven patients with positive RUS findings, the mean±SD days from first positive culture to RUS was 6.9±7.9; this was slightly higher than for all infants who underwent RUS, but sample size was small and SD was large. For the patients with positive RUS studies, the following outcomes occurred: three had resolution of the ultrasound findings while on antifungal therapy; three had persistence of findings possibly concerning for fungal renal involvement, but renal function was normal, subsequent repeat cultures were negative for fungus, and antifungal therapy was discontinued; and one patient did not have a repeat ultrasound. In that case, antifungal therapy was discontinued based on negative repeat cultures and normal renal function.
Of the eight patients who did not undergo RUS, four had positive fungal blood cultures only, one had a positive ETT culture only, and three had positive urine cultures only. Of those three patients with positive urine fungal cultures who did not undergo RUS, two were extremely premature, both with Gram-negative rod bacterial sepsis, severe progressive lung disease including pulmonary interstitial emphysema, and severe intraventricular hemorrhages. One of these patients died the day after the positive urine culture; the other had a negative repeat urine culture 2 days after the positive culture. The urine of the remaining patient had 
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been obtained by suprapubic aspiration, but nonetheless multiple organisms were isolated on culture. A repeat urine culture was obtained prior to initiating antifungal therapy, which was negative.
DISCUSSION
This analysis of 66 NICU patients with any positive culture for a Candida species over a 5 1 2 À year period, demonstrates that ancillary testing for organ involvement was frequently undertaken. However, evidence of fungal tissue dissemination was uncommon, with no positive findings on any echocardiogram or ophthalmologic examination, and only one case (in a patient with persistently positive cultures) in which brain imaging findings were consistent with fungal involvement. The diagnostic yield from RUS was higher than other tests, but these radiologic findings alone inconsistently influenced therapeutic decisions, suggesting that the approach to potentially positive examinations was highly individualized.
The optimal diagnostic approach to the neonate with a positive culture for Candida has yet to be clearly established. The decision to pursue ancillary diagnostic testing in this population may best be based on an understanding of the incidence of associated morbidities within each nursery; this may in turn vary depending on the background prevalence of Candida infection, the index of suspicion for fungal infections, and the aggressiveness with which Candida infections are treated. In our intensive care nursery, there is a relatively low incidence of Candidiasis, but there is also a high index of suspicion for fungal infections, and a low threshold for initiating diagnostic evaluation. If a culture from a sterile site returns positive for yeast, treatment is promptly initiated with fulldose amphotericin B (1 mg/kg/day), adding 5-fluorocytosine if indicated. Any indwelling central catheter is removed as soon as possible.
Other centers have reported experience with neonatal fungal cardiac dissemination. In a series of 86 neonates with candidemia, there was documented potential fungal cardiac pathology in 11 of the 72 patients studied (15.2%). 23 In a separate series of patients with acquired fungal sepsis, there was cardiac involvement in 6.6% of the patients studied with echocardiography. 7 However, in another study, cardiac involvement was identified in only one of 45 neonates with candidemia. 27 In two other smaller series, cardiac involvement was not identified in a total of 29 neonates with candidemia.
2,28 These differences may be reflective of disparate patient populations, diagnostic, or therapeutic approaches. It may be suggested that cardiac fungal involvement was potentially undiscovered in our experience, and that cardiac abnormalities might have been found in the two patients with candidemia who died prior to undergoing an echocardiogram. Unfortunately, neither family consented to an autopsy. It is also possible that the delay to echocardiogram for some of the patients may have resulted in ''missing'' the cardiac fungal involvement; but this is unlikely as the majority of the studies (85%) were obtained within 7 days. However, other authors have shown that a number of clinical factors failed to accurately predict fungal involvement by echocardiogram in patients with candidemia. 23 Thus, even in light of our relatively reassuring findings, and given the significant clinical implications of not detecting cardiac fungal involvement, we agree with previous recommendations that ancillary evaluations should be performed in all cases of neonatal candidemia. 29 Nevertheless, critical evaluation of how the results of a positive echocardiogram would affect patient management may give insights into the optimal timing of this examination. If the purpose of obtaining an echocardiogram is to assist in determining the length of therapy, it may be of low yield to pursue this study after only one positive culture for Candida. A potentially better approach may be to obtain an echocardiogram near the end of therapy in uncomplicated cases, and early in the course in cases of multiple positive cultures or known cardiac anomalies.
The yield of brain imaging is also controversial in this population. Some have advocated obtaining HUS in neonates with candidemia to assist in neurodevelopmental prognostication. 30 Another proposed rationale for pursuing brain imaging is the reported lack of sensitivity of CSF culture in the diagnosis of a Other authors, at centers in which amphotericin is begun empirically in the high-risk neonate with symptoms of Candida infection, have reported no HUS evidence of fungal dissemination among neonates with documented candidemia. 7 Others have supported the pursuit of aggressive imaging for ventriculitis only for infants with persistently positive blood cultures, or for those with strongly suggestive signs of focal CNS complications. 24 In our own series, only one case of brain fungal involvement was documented in a patient with persistently positive blood cultures for Candida albicans. Importantly, the HUS obtained after the first positive culture in that case was negative, yet subsequent brain imaging was grossly abnormal. This finding suggests that serial brain imaging may be valuable in cases of persistent candidemia, as others have described for RUS imaging. 17, 31 Ophthalmologic involvement in neonates with candidemia has been reported in 0% 7, 24 to 6% 23 of patients who underwent examinations. These cases demonstrate the importance of ophthalmologic examination in neonatal candidiasis, but currently available data are restricted primarily to clinical series, thus firm recommendations regarding timing of the examination cannot be made. One potential modification to the approach would be to obtain the ophthalmologic examination near the end of the antifungal therapy course, with an earlier examination in cases of persistent positive cultures.
In our series of patients, the ancillary test with the highest yield for identifying fungal-associated morbidity was RUS (7/58, 12%). There was considerable practice variation in the timing of the examination and response to the initial findings on ultrasound. This may reflect a lack of consensus on the need for obtaining this ancillary test as well as the definition of a ''positive'' finding. Previous reports demonstrated a 42% incidence of renal fungal involvement in a population of 41 infants with candiduria, 17 but other series have reported the incidence of abnormal RUS findings to be more consistent with our own at 4.6% 23 and 7.1%. 7 Irrespective of the incidence of fungal infiltration in the kidney, the therapeutic dilemma posed by abnormal RUS findings in the setting of normal renal function and negative repeat cultures remains. It has been suggested that ultrasound evidence of fungal involvement may persist after viable organisms are no longer present, 15 thus, as in three of the patients in this series, therapy may be discontinued even in the presence of persistent RUS findings consistent with fungal balls. It is somewhat reassuring that case reports of obstructive uropathy requiring nephrostomy described neonates with impaired renal function or renal failure. [32] [33] [34] In conclusion, in this analysis of intensive care nursery patients with Candida infection, ancillary testing for organ fungal dissemination was undertaken frequently, but was of overall low yield. Abnormal radiologic findings were weighed with multiple other factors in planning therapeutic management. We speculate that if diagnostic evaluations are performed based on a low threshold for suspecting fungal infection and therapy is aggressively initiated, extensive ancillary diagnostic investigation may not be required in all cases. However, currently available data exist only in case series and reports; differences in patient populations, diagnostic strategies, and small patient numbers make it impossible to reach consensus regarding the best approach to ancillary testing. Until larger, prospective studies are undertaken, and given the potentially devastating effects of organ fungal dissemination, ancillary evaluations for fungal organ involvement will continue in the neonatal population.
